HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy
*Cleveland Clinic, Cleveland, OH
†Mayo Clinic, Jacksonville, FL
‡University of California, San Francisco, San Francisco, CA
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: Karuna Garg, MD, Department of Pathology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 (e-mail: [email protected]).
留言 (0)